Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar:17:67-74.
doi: 10.1016/j.ebiom.2017.02.017. Epub 2017 Feb 20.

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development

Affiliations
Meta-Analysis

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development

Iris Rajman et al. EBioMedicine. 2017 Mar.

Abstract

Genetic diversity is greater in Africa than in other continental populations. Genetic variability in genes encoding drug metabolizing enzymes may contribute to the high numbers of adverse drug reactions reported in Africa. We reviewed publications (1995-April 2016) reporting frequencies of known cytochrome P450 (CYP) variants in African populations. Using principal components analysis (PCA) we identified CYP alleles of potential clinical relevance with a marked difference in distribution in Africa, compared with Asian and Caucasian populations. These were CYP2B6*6, CYP2C8*2, CYP2D6*3, CYP2D6*17, CYP2D6*29, CYP3A5*6, and CYP3A5*7. We show clearly that there is greater diversity in CYP distribution in Africa than in other continental populations and identify a need for optimization of drug therapy and drug development there. Further pharmacogenetic studies are required to confirm the CYP distributions we identified using PCA, to discover uniquely African alleles and to identify populations at a potentially increased risk of drug-induced adverse events or drug inefficacy.

Keywords: Africa; CYP450; Drug development; Drug metabolism; Genetic diversity; Pharmacogenetics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of study selection.
Fig. 2
Fig. 2
Pharmacogenetics PCA cluster of global populations according to different CYP allele frequencies. PCA analysis identifies X-variables (CYP variants) that most differentiate Y-objects (African/Asian/Caucasian populations). In this analysis, the software projects the populations into clusters based on shared characteristics with respect to the frequency and/or absence of the CYP variants analyzed. Green ovals indicate African populations. Blue ovals indicate Caucasian populations. Red ovals indicate Asian populations. Kikuyu, Luo and Maasai are regional populations of Kenya. Hausa, Igbo and Yoruba are regional populations of Nigeria. San and Shona are regional populations of Zimbabwe. Xhosa is a regional population of South Africa. CYP, cytochrome P450; PCA, principal components analysis.

References

    1. Alessandrini M., Pepper M.S. Priority pharmacogenetics for the African continent: focus on CYP450. Pharmacogenomics. 2014;15:385–400. - PubMed
    1. Ampadu H.H., Hoekman J., De Bruin M.L., Pal S.N., Olsson S., Sartori D., Leufkens H.G., Dodoo A.N. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39:335–345. - PMC - PubMed
    1. Bains R.K., Kovacevic M., Plaster C.A., Tarekegn A., Bekele E., Brandman N.N., Thomas M.G. Molecular diversity and population structure at the cytochrome p450 3A5 gene in Africa. BMC Genet. 2013;14:1–18. - PMC - PubMed
    1. Bell G.C., Caudle K.E., Whirl-Carillo M., Gordon R.J., Hikino K., Prows C.A., Gaedigk A., Agundez J.A., Sadhasivam S., Klein T.E., Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther. 2016 (Epub ahead of print) - PMC - PubMed
    1. Birdwell K.A., Decker B., Barbarino J.M., Peterson J.F., Stein C.M., Sadee W., Wang D., Vinks A.A., He Y., Swen J.J., Leeder J.S., Van Schaik R., Thummel K.E., Klein T.E., Caudle K.E., Macphee I.A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 2015;98 - PMC - PubMed

Publication types

Substances